A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this study was to evaluate the humoral immunogenicity and safety of 2 doses of GSK Biologicals\' Herpes Zoster subunit vaccine (HZ/su) administered for the prevention of Herpes Zoster (HZ) in adults aged 50 years of age (YOA) or older from India.
Epistemonikos ID: b4bfc84cc0e72feda893c1c22557c69f7c6fcf0f
First added on: May 10, 2024